Albireo Pharma Inc (ALBO) Stock
ALBO is no longer traded. Albireo Pharma was delisted from the Nasdaq in March 2023.
Prices on this page are historical; the last trade was March 2, 2023 at $44.15.
Albireo Pharma stock price history
ALBO final trading statistics
- Final close
- $44.15
- Final trading day
- Mar 2, 2023
- Market cap at delisting
- $915.89M
- Shares outstanding
- 20.74M
- Final 52-week range
- $16.02 – $45.23
- Avg. volume (final 3 mo.)
- 572,892
- All-time high (split-adj.)
- $3096.00 · Mar 2014
- All-time low (split-adj.)
- $6.90 · Dec 2015
- Return since IPO
- -98.0%
- Beta
- 1.04
- Book value / share
- $4.84
- Price / book
- 9.13
Albireo Pharma annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $40.58M | -$34.0M | -$1.86 |
| FY2020 | $8.31M | -$107.6M | -$6.87 |
| FY2019 | $9.64M | -$62.7M | -$5.04 |
| FY2018 | $12.74M | -$46.1M | -$3.88 |
| FY2017 | $1.0K | -$24.4M | -$3.20 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Albireo Pharma Inc
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts. As of March 1, 2023, Albireo Pharma, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..
Albireo Pharma stock FAQ
What happened to Albireo Pharma stock?
Albireo Pharma stock was delisted from the Nasdaq. Its final close was $44.15 on March 2, 2023.
Is ALBO stock still trading?
No. ALBO was delisted from the Nasdaq in March 2023 and no longer trades on a U.S. exchange.
What was the last price of ALBO stock?
ALBO closed at $44.15 on its final trading day, March 2, 2023, for a market value of about $915.89M.
What were Albireo Pharma's revenue and earnings in its last full fiscal year?
Albireo Pharma reported revenue of $40.58M and net income of -$34.0M in fiscal 2021, its last full year as a public company.
When did Albireo Pharma go public?
Albireo Pharma Inc stock began trading on May 11, 2007.